Close X
Get more out of WDDTY.com
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs
OR

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.


Click here if you're interested
Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!

Subscribe!

Astroturfing: Why the information on patient group sites can be suspect
About the author: 

There are plenty of tactics that drug companies employ in order to increase sales

There are plenty of tactics that drug companies employ in order to increase sales. Getting to doctors is easy enough: 'educational' trips to the Caribbean, sponsored staff canteens, payment for 'research projects' by putting patients onto new and untried drugs, and funding whole careers are just a few gambits they use.

But how to get to the patient directly? Short of straight advertising, one of the best techniques is known as 'astroturfing'. This involves funding patient groups that, in turn, start promoting the pro-drug message to unwitting members who just want unbiased information on their condition.

GlaxoSmithKline (GSK) has just been caught out 'astroturfing' a patients group called Ekbom Support Group, which helps advise people with restless legs syndrome.

GSK's advertising included a link through to the group's website, which described the company's drug ropinirole as an effective treatment for the problem.

Ropinirole was developed by GSK as an anti-Parkinson's drug, but is now marketed for restless legs syndrome under the brand name of Adartrel.

GSK was wrong to place the advertisements in the first place because they appeared eight months before the drug was approved. The drug company had also supported the Ekbom Support Group.

The Prescription Medicines Code of Practice Authority, which oversees drug advertising in the UK, ruled that GSK "was, in effect, directing patients to a website that contained misleading messages about the safety of ropinirole, which might indirectly encourage patients to ask their doctors to prescribe it."

(Source: www.pmcpa.org/completedcases, reference No. 1801/2/06).

E-news broadcast 24 August 2006 No.286 [Subscribe]


You may also be interested in...

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2017 WDDTY Publishing Ltd.
All Rights Reserved